44 research outputs found

    Squeaky Wheel: Thomas Bernhard and A Party for Boris

    Get PDF
    Though productions of his plays are extremely rare in North America, Austrian Thomas Bernhard (1931-1989) is one of the pillars of the European repertory, especially in theatrically progressive Germany. His bellicose, radically composed comedies teem with a discontentment tempered by sophisticated humor and astonishingly realistic relationships, all within the framework of a vehement non-Realism. This document chronicles my research into geo-political events and societal elements that shaped Bernhard, and my inquiries into the subject matter and style of his play A Party for Boris (Ein Fest fr Boris), which I have chosen to direct as my thesis production at York University

    Performance Characteristics of Polyethylene Terephthalate (PET) Modified Asphalt

    Get PDF
    Polyethylene terephthalate (PET) plastic is utilized primarily in food and beverage packaging. Although a portion of waste PET is recycled, the majority of the waste is buried in landfills. Therefore, the use of ground PET particles in asphalt may provide an environmentally friendly solution for the disposal of large quantities of PET waste. This study evaluated the performance of PET as an asphalt modifier with both asphalt binder and asphalt mixture testing. The binder testing was conducted on wet process blends produced with a high shear mixer at PET contents of 5, 10, and 15 percent by weight of the binder. Dynamic Shear Rheometer (DSR) and Rotational Viscosity (RV) tests were performed on the unaged and Rolling Thin Film Oven (RTFO) aged mixtures. The mixture tests were conducted on the PET modified mixtures in both wet and dry process, and an unmodified control mixture. The wet and dry process mixtures contained 10% PET by weight of the binder. The mixture performance tests included Asphalt Pavement Analyzer (APA) rutting test, retrofitted APA Hamburg test, Indirect Tensile Strength (ITS), and Asphalt mixture Performance Tester (AMPT) dynamic modulus. The results showed: 1) the addition of PET increased the high temperature performance resulting in a bump in PG grade. Additionally, the viscosity and resulting workability of the modified binders were not adversely affected. 2) PET modified mixtures have higher maximum specific gravity and lower bulk specific gravity than the control mixture. 3) The wet process mixture exhibited better rutting resistance and a higher TSR than the control in ITS testing. 4) The dry process mixture exhibited better resistance to permanent moisture damage in APA Hamburg testing and also exhibited a higher TSR than the control in ITS testing. 5) The modified mixtures exhibited lower E* and higher phase angles than the control in AMPT modulus testing

    Multiplex qPCR Discriminates Variants of Concern to Enhance Global Surveillance of SARS-CoV-2

    Get PDF
    With the emergence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) variants that may increase transmissibility and/or cause escape from immune responses, there is an urgent need for the targeted surveillance of circulating lineages. It was found that the B.1.1.7 (also 501Y.V1) variant, first detected in the United Kingdom, could be serendipitously detected by the Thermo Fisher TaqPath COVID-19 PCR assay because a key deletion in these viruses, spike Δ69-70, would cause a spike gene target failure (SGTF) result. However, a SGTF result is not definitive for B.1.1.7, and this assay cannot detect other variants of concern (VOC) that lack spike Δ69-70, such as B.1.351 (also 501Y.V2), detected in South Africa, and P.1 (also 501Y.V3), recently detected in Brazil. We identified a deletion in the ORF1a gene (ORF1a Δ3675-3677) in all 3 variants, which has not yet been widely detected in other SARS-CoV-2 lineages. Using ORF1a Δ3675-3677 as the primary target and spike Δ69-70 to differentiate, we designed and validated an open-source PCR assay to detect SARS-CoV-2 VOC. Our assay can be rapidly deployed in laboratories around the world to enhance surveillance for the local emergence and spread of B.1.1.7, B.1.351, and P.1

    Combining genomic and epidemiological data to compare the transmissibility of SARS-CoV-2 variants Alpha and Iota.

    Get PDF
    SARS-CoV-2 variants shaped the second year of the COVID-19 pandemic and the discourse around effective control measures. Evaluating the threat posed by a new variant is essential for adapting response efforts when community transmission is detected. In this study, we compare the dynamics of two variants, Alpha and Iota, by integrating genomic surveillance data to estimate the effective reproduction number (Rt) of the variants. We use Connecticut, United States, in which Alpha and Iota co-circulated in 2021. We find that the Rt of these variants were up to 50% larger than that of other variants. We then use phylogeography to show that while both variants were introduced into Connecticut at comparable frequencies, clades that resulted from introductions of Alpha were larger than those resulting from Iota introductions. By monitoring the dynamics of individual variants throughout our study period, we demonstrate the importance of routine surveillance in the response to COVID-19

    Proceedings of the Thirteenth International Society of Sports Nutrition (ISSN) Conference and Expo

    Get PDF
    Meeting Abstracts: Proceedings of the Thirteenth International Society of Sports Nutrition (ISSN) Conference and Expo Clearwater Beach, FL, USA. 9-11 June 201

    Fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin with gemtuzumab ozogamicin improves event-free survival in younger patients with newly diagnosed aml and overall survival in patients with npm1 and flt3 mutations

    Get PDF
    Purpose To determine the optimal induction chemotherapy regimen for younger adults with newly diagnosed AML without known adverse risk cytogenetics. Patients and Methods One thousand thirty-three patients were randomly assigned to intensified (fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin [FLAG-Ida]) or standard (daunorubicin and Ara-C [DA]) induction chemotherapy, with one or two doses of gemtuzumab ozogamicin (GO). The primary end point was overall survival (OS). Results There was no difference in remission rate after two courses between FLAG-Ida + GO and DA + GO (complete remission [CR] + CR with incomplete hematologic recovery 93% v 91%) or in day 60 mortality (4.3% v 4.6%). There was no difference in OS (66% v 63%; P = .41); however, the risk of relapse was lower with FLAG-Ida + GO (24% v 41%; P < .001) and 3-year event-free survival was higher (57% v 45%; P < .001). In patients with an NPM1 mutation (30%), 3-year OS was significantly higher with FLAG-Ida + GO (82% v 64%; P = .005). NPM1 measurable residual disease (MRD) clearance was also greater, with 88% versus 77% becoming MRD-negative in peripheral blood after cycle 2 (P = .02). Three-year OS was also higher in patients with a FLT3 mutation (64% v 54%; P = .047). Fewer transplants were performed in patients receiving FLAG-Ida + GO (238 v 278; P = .02). There was no difference in outcome according to the number of GO doses, although NPM1 MRD clearance was higher with two doses in the DA arm. Patients with core binding factor AML treated with DA and one dose of GO had a 3-year OS of 96% with no survival benefit from FLAG-Ida + GO. Conclusion Overall, FLAG-Ida + GO significantly reduced relapse without improving OS. However, exploratory analyses show that patients with NPM1 and FLT3 mutations had substantial improvements in OS. By contrast, in patients with core binding factor AML, outcomes were excellent with DA + GO with no FLAG-Ida benefit
    corecore